Citigroup
SLDB icon

Citigroup’s Solid Biosciences SLDB Stock Holding History

Citigroup’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Buy
148,432
+79,056
+114% +$599K ﹤0.01% 3157
2026
Q1 		$500K Buy
69,376
+65,869
+1,878% +$423K ﹤0.01% 3547
2025
Q4 		$19.8K Sell
3,507
-2,685
-43% -$14.6K ﹤0.01% 4874
2025
Q3 		$38.2K Sell
6,192
-46,182
-88% -$270K ﹤0.01% 4570
2025
Q2 		$255K Buy
52,374
+34,291
+190% +$121K ﹤0.01% 3950
2025
Q1 		$66.9K Buy
18,083
+428
+2% +$1.83K ﹤0.01% 4790
2024
Q4 		$70.6K Buy
17,655
+1,045
+6% +$5.74K ﹤0.01% 4973
2024
Q3 		$116K Buy
16,610
+11,569
+229% +$93.8K ﹤0.01% 4701
2024
Q2 		$28.6K Sell
5,041
-42,671
-89% -$382K ﹤0.01% 4885
2024
Q1 		$636K Buy
+47,712
New +$446K ﹤0.01% 3403
2022
Q4 		– Sell
-98
Closed -$1K – 5939
2022
Q3 		$1K Sell
98
-56
-36% -$565 ﹤0.01% 5685
2022
Q2 		$1K Sell
154
-228
-60% -$2.37K ﹤0.01% 6087
2022
Q1 		$7K Sell
382
-1,332
-78% -$23.5K ﹤0.01% 5703
2021
Q4 		$45K Buy
1,714
+1,245
+265% +$38K ﹤0.01% 5121
2021
Q3 		$17K Buy
469
+33
+8% +$1.4K ﹤0.01% 5300
2021
Q2 		$24K Buy
436
+65
+18% +$4.29K ﹤0.01% 5203
2021
Q1 		$31K Sell
371
-260
-41% -$28.8K ﹤0.01% 4991
2020
Q4 		$72K Buy
631
+243
+63% +$15.4K ﹤0.01% 5792
2020
Q3 		$12K Sell
388
-65
-14% -$2.49K ﹤0.01% 6512
2020
Q2 		$20K Sell
453
-71
-14% -$2.95K ﹤0.01% 6623
2020
Q1 		$19K Sell
524
-51
-9% -$2.52K ﹤0.01% 6737
2019
Q4 		$38K Sell
575
-950
-62% -$105K ﹤0.01% 6538
2019
Q3 		$237K Buy
1,525
+2
+0.1% +$226 ﹤0.01% 5018
2019
Q2 		$131K Buy
1,523
+26
+2% +$2.83K ﹤0.01% 5626
2019
Q1 		$207K Sell
1,497
-3,240
-68% -$812K ﹤0.01% 5065
2018
Q4 		$1.9M Buy
4,737
+4,500
+1,899% +$2.12M ﹤0.01% 2726
2018
Q3 		$168K Buy
237
+123
+108% +$77.3K ﹤0.01% 5426
2018
Q2 		$61K Sell
114
-2
-2% -$615 ﹤0.01% 6133
2018
Q1 		$13K Buy
+116
New +$39.2K ﹤0.01% 6942

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citigroup's SLDB Position: Q2 2026 in Review

Citigroup increased its Solid Biosciences (SLDB) stake by 114% in Q2 2026, buying an estimated $599K and bringing the position to 148,432 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3157.

Citigroup first reported a position in SLDB in Q1 2018 and has held it in 29 quarters since. The position peaked at $1.9M in Q4 2018. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Citigroup held 148,432 shares of Solid Biosciences worth $1.48M as of Q2 2026.
  • Citigroup bought 79,056 Solid Biosciences shares in Q2 2026, an estimated $599K.
  • Solid Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3157 holding.
  • Citigroup first reported a position in Solid Biosciences in Q1 2018 and has held it in 29 quarters since.
  • Citigroup's Solid Biosciences position peaked at $1.9M in Q4 2018.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.